Where to find the pick of the bunch in biotech stocks

Professional investor Ailsa Craig picks three biotech stocks generating revenues and profits, and which have long-term patent protection.

Each week, a professional investor tells us where she'd put her money. This week: Ailsa Craig of the International Biotechnology Trust chooses three promising small caps.

Biotechnology remains an exciting sector, but investors need to be far more discriminating now than they were a few years ago. Growth at the largest firms has slowed, as popular products have reached their peak sales potential. There is now more scope for long-term earnings growth in smaller and medium-sized companies.

However, many of the smaller firms carry greater risk than their larger counterparts. They often do not have wellestablished portfolios of existing drugs and future earnings depend on the launch of new products. Also, drug development is a challenging, long-term business with no guarantees of success.

To avoid undue risk, investors should select companies with products that generate revenues and profits, and also have long-term patent protection. Here are three stocks that match this profile.

Turbulent but promising

Incyte (Nasdaq: INCY) has had a turbulent 18 months. It was developing a new type of cancer therapy an IDO-inhibitor', which works by stopping cancer cells from hijacking the IDO protein, which can suppress the immune system.

There were high hopes for the treatment, but a final study in April revealed the treatment regime was ineffective. As a result, the share price fell sharply and the stock is now trading at less than half the value it reached at its peak.

Despite the failure of the IDO-inhibitor, all is not lost. Incyte's multi-billion-dollar drug, Jakafi, is used to treat patients with a rare form of blood cancer for whom existing treatments are ineffective. Jakafi has recently received approval for a second indication in other words, it could be used for another disease and strong growth is expected to continue.

The company also has a lucrative agreement with Eli Lilly for another recently-approved product, Baricitinib, which is expected to generate additional revenues in the medium-term.

A cystic-fibrosis specialist

Vertex (Nasdaq: VRTX) has a significant market cap, but it does not have the structural problems of other large biotech companies. The company specialises in the treatment of cystic fibrosis; its product, Kalydeco, works by modifying the disease, and is very effective.

As cystic fibrosis only affects a relatively small number of patients, the company has received orphan drug' status for Kalydeco. This permits the company to charge a high price for the drug and the compound is protected from competitors. In addition, Vertex owns the drug outright so it is not sharing profits with a larger partner. Earnings-per-share are set to double over the next three years.

Attacking early-stage cancer

Genmab (Copenhagen: GEN) currently has two drugs on the market, one of which is Darzalex. The main growth-driver, this compound is a monoclonal antibody used to treat multiple myeloma, a rare form of cancer.

Darzalex is now approved for use in patients with earlier stages of the disease, which should give Genmab's revenues a considerable boost. The company is also developing a formulation of the drug that is easier to administer, which will cut infusion time substantially. This will lead to increased patient numbers and improve their quality of life.

Recommended

Buy into the “contrarian” appeal of US growth stocks
Investment trusts

Buy into the “contrarian” appeal of US growth stocks

Investors should ignore the shift towards value stocks, says Max King, and stick with fast-growing American tech stocks. Here are two of the best inve…
26 Jan 2021
Three clean energy stocks for your portfolio
Share tips

Three clean energy stocks for your portfolio

Professional investor Christian Roessing of the Pictet Clean Energy Fund highlights of his three favourite stocks at the forefront of the clean energy…
25 Jan 2021
Eternal growth: how to invest in the future of the drinks industry
Share tips

Eternal growth: how to invest in the future of the drinks industry

Humans have been dabbling in tasty beverages for millennia. Jonathan Compton assesses the key trends in the sector and recommends seven hard- and soft…
22 Jan 2021
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
22 Jan 2021

Most Popular

The FTSE 100 is set for a makeover with an influx of new tech stocks
UK stockmarkets

The FTSE 100 is set for a makeover with an influx of new tech stocks

The FTSE 100 – the dullest index in the world – is about to reinvent itself as a host of new firms list on the market. The change is long overdue, say…
24 Jan 2021
Think Tesla is a bubble? This might be the best way to bet on it bursting
Oil

Think Tesla is a bubble? This might be the best way to bet on it bursting

The huge rise in Tesla’s share price means that, by market value, it’s now the sixth-largest company in the US and and the world’s biggest car-maker. …
25 Jan 2021
Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021